All In Biotech

Drug Trial Radar · NCT06741072

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

A Phase 1B Double Blinded Randomized Trial Evaluating Safety, Tolerability, and Immune Response of OSU-2131 a BZLF1 Peptide Vaccine With Stimulon™ QS-21 Solution Adjuvant in Healthy Volunteers and Patients Awaiting Solid Organ Transplantation

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Jun 28, 2026

Primary completion

Jul 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Ohio State University Comprehensive Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and related cancers in healthy volunteers and patients awaiting a solid organ transplant. Currently, patients who receive an organ transplant receive immune suppression therapy which can make it harder for the body to fight infections. This treatment also increases the risk for cancers that are triggered by the EBV. Vaccines made from synthetic peptide (RAKFKQLL) derived from the BZLF1 protein, may help the body build an effective immune response against EBV infections. QS-21, a saponin adjuvant, is a substance from plants that, when given with vaccine therapy, may improve the way the immune system responds to disease. Giving OSU-2131 with QS-21 may help the immune system fight EBV and protect against EBV infection and the cancers that it can cause in patients awaiting solid organ transplants.

Conditions

  • Chronic Kidney Disease, Stage 4
  • Chronic Kidney Disease, Stage 5
  • EBV-Related Lymphoproliferative Disorder
  • EBV-Related Malignant Neoplasm
  • Post-Transplant Lymphoproliferative Disorder

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Dulbecco''s Phosphate-Buffered SalineDrug

    Given SC

  • Peptide VaccineBiological

    Given OSU-2131 SC

  • QS21Biological

    Given SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: From the first administration of treatment until the week 28 visit
  2. Changes in laboratory parameters and vital signsTime frame: At baseline and up to week 56
  3. Pre- and post-injection vital signsTime frame: Up to week 4
  4. Injection site reactionsTime frame: At 10 and/or 60 minutes post injection on weeks 0, 2 and 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.